Dermata Therapeutics (NASDAQ:DRMAW – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
Profitability
This table compares Dermata Therapeutics and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | N/A | N/A |
| Beauty Health | -9.79% | -47.83% | -5.79% |
Earnings & Valuation
This table compares Dermata Therapeutics and Beauty Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | N/A | N/A | N/A |
| Beauty Health | $290.05 million | 0.30 | -$9.52 million | ($0.22) | -3.03 |
Dermata Therapeutics has higher earnings, but lower revenue than Beauty Health.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Dermata Therapeutics and Beauty Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Beauty Health | 1 | 5 | 1 | 0 | 2.00 |
Beauty Health has a consensus target price of $1.38, indicating a potential upside of 106.15%. Given Beauty Health’s stronger consensus rating and higher probable upside, analysts clearly believe Beauty Health is more favorable than Dermata Therapeutics.
Insider and Institutional Ownership
93.3% of Beauty Health shares are held by institutional investors. 40.3% of Beauty Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Beauty Health beats Dermata Therapeutics on 6 of the 9 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
